Novo Nordisk and Aarhus University team up on world-class talents
- Details
- Category: Novo Nordisk
Novo Nordisk and Aarhus University's Science and Technology faculty today signed a collaboration agreement to strengthen protein technology research and development. Under the new collaboration, a total of nine PhD students will be offered three-year research scholarships.
AstraZeneca enters licensing agreements with LEO Pharma in skin diseases
- Details
- Category: AstraZeneca
AstraZeneca today announced that it has entered into agreements that support its strategic focus on three main therapy areas; Respiratory, Inflammation and Autoimmunity, Cardiovascular and Metabolic disease and Oncology. The agreements include two of AstraZeneca's potential new medicines for dermatitis and psoriasis,
Bristol-Myers Squibb and PsiOxus Therapeutics announce immuno-oncology clinical collaboration
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an exclusive clinical collaboration agreement to evaluate the safety, tolerability, and preliminary efficacy of PsiOxus' enadenotucirev, a systemically administered oncolytic adenovirus therapeutic, in combination with Bristol-Myers Squibb's Immuno-Oncology (I-O) agent Opdivo (nivolumab) to treat a range of tumor types in late-stage cancer patients.
Novartis adds bispecific antibodies to its growing immuno-oncology portfolio through collaboration and licensing agreement with Xencor
- Details
- Category: Novartis
Today Novartis announced that it has entered into a collaboration and licensing agreement with Xencor for the development of bispecific antibodies for treating cancer. The agreement is the latest in a series of acquisitions and strategic collaborations between Novartis and biotech companies that have helped bolster its deep and diverse immuno-oncology pipeline.
New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections
- Details
- Category: AstraZeneca
AstraZeneca today announced that the European Commission (EC) has granted marketing authorisation for Zavicefta (ceftazidime-avibactam, previously known as CAZ AVI), a new combination antibiotic for the treatment of patients with serious Gram-negative bacterial infections requiring hospitalisation.
Pfizer completes acquisition of Anacor
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) today announced that it has completed its acquisition of Anacor Pharmaceuticals, Inc. Under the terms of the transaction, each outstanding share of Anacor common stock has been converted into the right to receive $99.25 net in cash (without interest but subject to required withholding of taxes).
Amgen Golden Ticket winners receive lab space and other benefits at QB3@953
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) today announced a five-year, platinum sponsorship of the QB3@953 life sciences incubator to accelerate the development of new therapies to improve human health. The shared laboratory space at QB3@953 was created to help high-potential life science and biotech startups overcome a key obstacle for many early stage organizations - access to laboratory infrastructure.
More Pharma News ...
- Help Pfizer change the future of healthy aging
- Merck Family Foundation established
- Roche employees raise funds for vulnerable children in over 90 communities around the world
- Sanofi announces expiration of Hart-Scott-Rodino waiting period regarding proposed acquisition of Medivation
- Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment
- Merck in agreement with HAPPYneuron to offer first-of-its kind e-Health solution for people living with multiple sclerosis
- Merck Accelerator expands its reach to Silicon Valley